Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid
This disclosure relates to a composition for the prevention or the treatment of inflammatory skin diseases or severe pruritus comprising an aqueous solubilized ursodeoxycholic acid (UDCA). According to this disclosure, inflammatory skin diseases and severe pruritus such as atopic dermatosis, acne, psoriasis, hives, inflammatory skin disease, seborrheic dermatitis and contact dermatitis can be effectively alleviated or treated. Therefore, the composition comprising aqueous solubilized ursodeoxycholic acid of this disclosure can be best used as a pharmaceutical, food or cosmetic composition, and can be used particularly as an external preparation to exhibit its effect.
1. A skin treatment cream for treatment of psoriasis comprising:
a composition comprising:
at least one bile acid salt selected from an ursodeoxycholic acid (UDCA), a tauroursodeoxycholic acid and a glycoursodeoxycholic acid;
an aqueous soluble starch conversion product; and
water, wherein the composition has pH values of 2.9-9.0,
the skin treatment cream further comprising:
Carbomer mixed with the composition;
Caprylic/Capric triglyceride mixed with the composition and having a weight percentage less than that of the composition;
isopropylisostearate, Stearyl alcohol, Dimethicone, and Cetearyl alcohol, all mixed with the composition, the isopropylisostearate having a weight percentage greater than that of the Stearyl alcohol, the Stearyl alcohol having a weight percentage greater than that of the Cetearyl alcohol; and
one or more of PEG-100 stearate, Glyceryl stearate, Sorbitan stearate, Ethylhexanediol, Tromethamine, or Tocopheryl acetate, mixed with the composition,
wherein the Carbomer has a weight percentage less than that of the composition,
wherein the Carbomer has a weight percentage less than that of the Caprylic/Capric triglyceride, and
wherein the aqueous soluble starch conversion product is maltodextrin and the weight ratio of the at least one bile acid salt to the maltodextrin is 1:30.
2. The skin treatment cream of claim 1 , wherein the one or more of PEG-100 stearate, Glyceryl stearate, Sorbitan stearate, Ethylhexanediol, Tromethamine, or Tocopheryl acetate, comprise all of PEG-100 stearate, Glyceryl stearate, Sorbitan stearate, Ethylhexanediol, Tromethamine, and Tocopheryl acetate, all mixed with the composition.
3. The skin treatment cream of claim 1 , wherein the one or more of PEG-100 stearate, Glyceryl stearate, Sorbitan stearate, Ethylhexanediol, Tromethamine, or Tocopheryl acetate, comprise all of PEG-100 stearate, Glyceryl stearate, Sorbitan stearate, and Ethylhexanediol, all mixed with the composition.
4. The skin treatment cream of claim 3 , wherein the PEG-100 stearate has a weight percentage same as that of the Glyceryl stearate, the Glyceryl stearate having a weight percentage greater than that of the Sorbitan stearate, the Sorbitan stearate having a weight percentage greater than that of the Ethylhexanediol.
5. The skin treatment cream of claim 2 , wherein the Tromethamine and the Tocopheryl acetate have same weight percentage.